Home

HARMONY

 

MDS-2: A retrospective study of patients with Myelodysplastic Syndrome
Inspiring HARMONY Alliance General Assembly 2021 - 6th edition HARMONY - 2nd edition HARMONY PLUS
CLL-2: Exploring the occurrence of other malignancies in CLL patients using the HARMONY BigData platform
ALL: Delphi Survey Project: Towards a Core Outcome Set for Acute Lymphoblastic Leukemia (ALL)
PRESS RELEASE: New HARMONY CML Research Project will study the role of genetic aberrations in the disease course of Chronic Myeloid Leukemia.
PRESS RELEASE: HARMONY presents new insights in Chronic Lymphocytic Leukemia at EHA2021
Connect with us at the EHA2021 Virtual Congress and learn about new HARMONY results
#Bigdataforbloodcancer Blog: Selecting the right treatment for the right patient: The HARMONY approach.
#Bigdataforbloodcancer Blog: The HARMONY Alliance - a balance between Big Data and Cybersecurity, with a real impact on patients with Hematological tumors
CLL: Delphi Survey Project: Towards a Core Outcome Set for Chronic Lymphocytic Leukemia
MM-2: Contextualizing clinical trials by developing robust historical control arm cohort
AML-5: Exploring a role for HARMONY data as historical control in elderly Acute Myeloid Leukemia patients.
AML-4: Using big data to confirm the link between MRD and survival in AML
AML-3: Using big data to shed light on the clinical impact of genomic alterations in sAML/tAML
ALL-4: Harnessing the Power of Big Data to Predict Outcomes Post-Stem Cell Transplant in Adult R/R ALL
ALL-3: Exploring treatment patterns and outcomes in older adult B-ALL
MM: Delphi Survey Project: Towards a Core Outcome Set for Multiple Myeloma
MDS: Delphi Survey Project: Towards a Core Outcome Set for Myelodysplastic Syndromes
ALL 2: Prognostic Value of IKZF1 Gene Alternations in Adult BCP ALL
NHL: Delphi Survey Project: Towards a Core Outcome Set for Non-Hodgkin Lymphoma
AML: Delphi Survey: Towards a Core Outcome Set for Acute Myeloid Leukemia
NHL: Using big data to optimize outcomes in T-cell Non-Hodgkin Lymphomas
MM-1: Optimizing prognostication and personalizing treatment in Multiple Myeloma
MDS-1: Prognostic factors to hypomethylating agents and intensive chemotherapy in higher risk Myelodysplastic Syndromes
1-24   25-48